EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Advancements of CRISPR/Cas9 technology and its value in antiviral therapeutics

Kapil Dev, Jubeda Begum, Nasir Akbar Mir, Rajiv Kant

Letters In Animal Biology · 2021

DOI: 10.62310/liab.v1i1.60 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Letters In Animal Biology, 2021. Verfasst von Kapil Dev und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CISPR/Cas9 system is a natural immune mechanism adopted by bacteria and archaea on exposure to invading phages and plasmids. The field of genome editing has been revolutionized with the advent of CRISPR/Cas9 technology. The CRISPR/Cas9 based gene editing has offered a promising therapeutic platform for many animal and human diseases, particularly viral diseases because viruses evolve constantly and hence escape vaccine-induced immunity. The targeted genome editing by RNA-guided nucleases is rapid, easy, economical, and efficient compared to previous editing technologies. It not only helps in the direct destruction of viruses, but also helps us understand the host-virus interactions, gene functions, and develop recombinant vaccines. It has been widely experimented in the field of antiviral therapy, starting with HIV in 2013 to SARS CoV-2 recently, with a series of modifications in structure and composition of CRISPR/Cas9 and delivery mechanisms to achieve the ever-increasing promising results. Herein, this review focused on the origin of CRISPR/Cas9 system, mechanism of action, advantages over existing gene-editing tools, its progress in antiviral therapy, vaccine development, delivery approaches, and challenges faced in the application of CRISPR/Cas9.

Zitieren

APA

Dev, K., Begum, J., Mir, N. A., & Kant, R. (2021). Advancements of CRISPR/Cas9 technology and its value in antiviral therapeutics. Letters In Animal Biology. https://doi.org/10.62310/liab.v1i1.60

Vancouver

Dev K, Begum J, Mir NA, Kant R. Advancements of CRISPR/Cas9 technology and its value in antiviral therapeutics. Letters In Animal Biology. 2021. doi:10.62310/liab.v1i1.60

BibTeX
@article{Dev2021,
  author = {Dev, Kapil and Begum, Jubeda and Mir, Nasir Akbar and Kant, Rajiv},
  title = {Advancements of CRISPR/Cas9 technology and its value in antiviral therapeutics},
  journal = {Letters In Animal Biology},
  year = {2021},
  doi = {10.62310/liab.v1i1.60}
}
Kostenlos starten →